| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,090,000 |
| Market
Cap: |
286.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.84 - $22.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,000 |
29,564 |
33,364 |
41,023 |
| Total Sell Value |
$168,600 |
$445,409 |
$513,847 |
$580,710 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
5 |
6 |
11 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Jason Drew |
General Counsel |
• • – |
2022-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,333 |
15,782 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-08-01 |
4 |
S |
$7.81 |
$2,023 |
D/D |
(259) |
23,708 |
|
-7% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-07-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
23,967 |
|
- |
|
| Nussbaum Ran |
Director |
• • – |
2022-06-16 |
4 |
OE |
$5.00 |
$11,055 |
I/I |
2,211 |
1,437,169 |
|
- |
|
| Nussbaum Ran |
Director |
• • – |
2022-06-06 |
4/A |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,434,958 |
|
- |
|
| Nussbaum Ran |
Director |
• • – |
2022-06-06 |
4 |
OE |
$5.00 |
$5,150 |
I/I |
1,030 |
1,433,928 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-04-30 |
4 |
S |
$6.62 |
$1,681 |
D/D |
(254) |
23,467 |
|
-25% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
23,721 |
|
- |
|
| Kim Dong |
Chief Financial OfficerOfficer |
• – – |
2022-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
31,920 |
|
-4% |
|
| Smith Jason Drew |
General Counsel |
• – – |
2022-01-31 |
4 |
S |
$7.58 |
$3,138 |
D/D |
(414) |
7,449 |
|
9% |
|
| Smith Jason Drew |
General Counsel |
• – – |
2022-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
833 |
7,863 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2022-01-31 |
4 |
S |
$7.58 |
$62,118 |
D/D |
(8,195) |
308,358 |
|
9% |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2022-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,333 |
314,318 |
|
- |
|
| Henderson Molly |
Chief Financial Officer |
• – – |
2022-01-31 |
4 |
S |
$7.58 |
$2,509 |
D/D |
(331) |
5,248 |
|
9% |
|
| Henderson Molly |
Chief Financial Officer |
• – – |
2022-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
666 |
5,579 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2022-01-31 |
4 |
S |
$7.58 |
$10,415 |
D/D |
(1,374) |
23,221 |
|
9% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2022-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
24,320 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2022-01-26 |
4 |
S |
$8.09 |
$898 |
D/D |
(111) |
22,095 |
|
21% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2022-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
209 |
22,206 |
|
- |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2022-01-04 |
4 |
S |
$9.15 |
$429,757 |
D/D |
(46,968) |
298,220 |
|
34% |
|
| Barrett Elizabeth A. |
Chief Executive Officer |
• – – |
2022-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
105,689 |
345,188 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2021-11-18 |
4 |
B |
$13.10 |
$2,096 |
D/D |
160 |
21,997 |
2.66 |
-30% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2021-11-01 |
4 |
S |
$17.16 |
$4,427 |
D/D |
(258) |
21,837 |
|
50% |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2021-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
22,095 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• – – |
2021-10-27 |
4 |
S |
$16.32 |
$1,746 |
D/D |
(107) |
21,595 |
|
44% |
|
156 Records found
|
|
Page 2 of 7 |
|
|
0.10 (0.77%) 
